DOSES AND METHODS OF ADMINISTERING TELAVANCIN

(19)

(11)

EP 3 261 658 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	05.06.2019 Bulletin 2019/23

(45)	Mention of the grant of the patent:
	03.04.2019 Bulletin 2019/14

(21)	Application number: 16708853.3

(22)	Date of filing: 18.02.2016

(51)

International Patent Classification (IPC):

A61K 38/12^(2006.01)

A61P 31/00^(2006.01)

(86)	International application number:
	PCT/US2016/018396

(87)	International publication number:
	WO 2016/137806 (01.09.2016 Gazette 2016/35)

(54)	DOSES AND METHODS OF ADMINISTERING TELAVANCIN DOSEN UND VERFAHREN ZUR VERABREICHUNG VON TELAVANCIN DOSES ET PROCÉDÉS D'ADMINISTRATION DE TÉLAVANCINE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME

(30)

Priority:

23.02.2015 US 201562119592 P

(43)	Date of publication of application:
	03.01.2018 Bulletin 2018/01

(73)	Proprietor: Cumberland Pharmaceuticals Inc.
	Nashville, TN 37203 (US)

(72)	Inventors:
	BARRIERE, Steven L. San Francisco, California 94115 (US) LO, Arthur San Francisco, California 94122 (US) MAMMEN, Mathai Menlo Park, California 94025 (US) WORBOYS, Philip San Mateo, California 94402 (US)

(74)	Representative: Bassil, Nicholas Charles
	Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL London WC1X 8NL (GB)

(56)

References cited: :

WO-A2-2005/042568

G. R. COREY ET AL: "Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 58, no. 4, 1 April 2014 (2014-04-01), pages 2030-2037, XP055271375, US ISSN: 0066-4804, DOI: 10.1128/AAC.02330-13
T. P. LODISE ET AL: "Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 56, no. 4, 1 April 2012 (2012-04-01), pages 2062-2066, XP055271388, US ISSN: 0066-4804, DOI: 10.1128/AAC.00383-11
ETHAN RUBINSTEIN ET AL: "Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia", EXPERT OPINION ON PHARMACOTHERAPY, vol. 12, no. 17, 15 December 2011 (2011-12-15), pages 2737-2750, XP055271400, LONDON, UK ISSN: 1465-6566, DOI: 10.1517/14656566.2011.633511
M. P. PAI: "Comment on: Acute renal insufficiency during telavancin therapy in clinical practice", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY., vol. 67, no. 5, 13 February 2012 (2012-02-13), pages 1300-1301, XP055271518, GB ISSN: 0305-7453, DOI: 10.1093/jac/dks029
SAMUEL ERIC WILSON ET AL: "Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections", INFECTION AND DRUG RESISTANCE, 1 March 2011 (2011-03-01), page 87, XP055293510, DOI: 10.2147/IDR.S5327

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).